Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma

J. Albert Fernandez-Pol, James Fletcher, Paul D. Hamilton, Dennis J. Klos

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background. We have previously shown that human metallopanstimulin (MPS-1) is a 9.4-kDa multifunctional ribosomal S27/nuclear 'zinc finger' protein which is expressed in a wide variety of actively proliferating cells and tumor tissues. Furthermore, we have shown that detection of MPS-N immunoreactive material in sera corresponding to the NH2 terminus of MPS-1 provides a method for determining the presence of certain types of abnormal proliferative conditions and/or active oncogenic processes in patients. In this study, we investigated MPS-N and MPS-N-like antigens present in the blood of patients with prostatic carcinoma (PC) and their relationship to the clinical status of patients with PC. Methods. The presence of MPS-N immunoreactive material was determined using a sensitive and specific radioimmunoassay (RIA) which has been developed to measure circulating levels of MPS-N antigen(s). In addition, MPS-N levels were compared to the primary bio-marker used in PC patient management, Prostatic Specific Antigen (PSA). Results. MPS-N concentations were determined in the blood of 107 males having no evidence of PC, and in 126 patients diagnosed with PC. In patients not having PC the MPS-N levels were lower than 10 ng/mL. In untreated patients having PC stages T1/T2, the MPS-N level range was 10-30 ng/mL; in stages T3/T4 the MPS-N level range was 30-50 ng/mL; and in stage Mlb (distant metastasis to the bones) the MPS-N levels were extremely high (> 50 ng/mL). In Mlb patients that did not respond to therapy the MPS-N levels remained very high (> 50 ng/mL). In Mlb patients that went into remission after treatment, the MPS-N levels were dramatically reduced. In addition, a comparison of the test properties of MPS-N and PSA for prostate cancer were evaluated in a total of 231 patients. In both the low and high value range, both MPS-N and PSA appear to be equally effective in modifying the probability of the target condition-prostatic cancer. Conclusions: These findings show that (1) in untreated PC patients, the increase in serum MPS-N correlated with the stage of the disease; (2) MPS-N tumor marker predicted the degree of aggressiveness of tumor growth and response to therapy. In summary despite the uncertainties of the relative contributions of the molecules being measured in cancer patients (authentic MPS-1, and MPS-N-like protein sequences), the MPS-N test is a pragmatic test that correlates well with active prostatic malignancy.

Original languageEnglish (US)
Pages (from-to)1519-1530
Number of pages12
JournalAnticancer Research
Volume17
Issue number3 A
StatePublished - 1997
Externally publishedYes

Fingerprint

Carcinogenesis
Carcinoma
Antigens
Neoplasms
Prostatic Neoplasms
Zinc Fingers
Tumor Biomarkers
Serum
Uncertainty
Radioimmunoassay
Proteins
Therapeutics
Neoplasm Metastasis
Bone and Bones
Growth

Keywords

  • Metallopanstimulin
  • Prostate cancer
  • Ribosomal S27 protein
  • Tumor markers
  • Zing finger proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fernandez-Pol, J. A., Fletcher, J., Hamilton, P. D., & Klos, D. J. (1997). Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma. Anticancer Research, 17(3 A), 1519-1530.

Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma. / Fernandez-Pol, J. Albert; Fletcher, James; Hamilton, Paul D.; Klos, Dennis J.

In: Anticancer Research, Vol. 17, No. 3 A, 1997, p. 1519-1530.

Research output: Contribution to journalArticle

Fernandez-Pol, JA, Fletcher, J, Hamilton, PD & Klos, DJ 1997, 'Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma', Anticancer Research, vol. 17, no. 3 A, pp. 1519-1530.
Fernandez-Pol, J. Albert ; Fletcher, James ; Hamilton, Paul D. ; Klos, Dennis J. / Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma. In: Anticancer Research. 1997 ; Vol. 17, No. 3 A. pp. 1519-1530.
@article{4e8cc48939c541759fdf900171308262,
title = "Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma",
abstract = "Background. We have previously shown that human metallopanstimulin (MPS-1) is a 9.4-kDa multifunctional ribosomal S27/nuclear 'zinc finger' protein which is expressed in a wide variety of actively proliferating cells and tumor tissues. Furthermore, we have shown that detection of MPS-N immunoreactive material in sera corresponding to the NH2 terminus of MPS-1 provides a method for determining the presence of certain types of abnormal proliferative conditions and/or active oncogenic processes in patients. In this study, we investigated MPS-N and MPS-N-like antigens present in the blood of patients with prostatic carcinoma (PC) and their relationship to the clinical status of patients with PC. Methods. The presence of MPS-N immunoreactive material was determined using a sensitive and specific radioimmunoassay (RIA) which has been developed to measure circulating levels of MPS-N antigen(s). In addition, MPS-N levels were compared to the primary bio-marker used in PC patient management, Prostatic Specific Antigen (PSA). Results. MPS-N concentations were determined in the blood of 107 males having no evidence of PC, and in 126 patients diagnosed with PC. In patients not having PC the MPS-N levels were lower than 10 ng/mL. In untreated patients having PC stages T1/T2, the MPS-N level range was 10-30 ng/mL; in stages T3/T4 the MPS-N level range was 30-50 ng/mL; and in stage Mlb (distant metastasis to the bones) the MPS-N levels were extremely high (> 50 ng/mL). In Mlb patients that did not respond to therapy the MPS-N levels remained very high (> 50 ng/mL). In Mlb patients that went into remission after treatment, the MPS-N levels were dramatically reduced. In addition, a comparison of the test properties of MPS-N and PSA for prostate cancer were evaluated in a total of 231 patients. In both the low and high value range, both MPS-N and PSA appear to be equally effective in modifying the probability of the target condition-prostatic cancer. Conclusions: These findings show that (1) in untreated PC patients, the increase in serum MPS-N correlated with the stage of the disease; (2) MPS-N tumor marker predicted the degree of aggressiveness of tumor growth and response to therapy. In summary despite the uncertainties of the relative contributions of the molecules being measured in cancer patients (authentic MPS-1, and MPS-N-like protein sequences), the MPS-N test is a pragmatic test that correlates well with active prostatic malignancy.",
keywords = "Metallopanstimulin, Prostate cancer, Ribosomal S27 protein, Tumor markers, Zing finger proteins",
author = "Fernandez-Pol, {J. Albert} and James Fletcher and Hamilton, {Paul D.} and Klos, {Dennis J.}",
year = "1997",
language = "English (US)",
volume = "17",
pages = "1519--1530",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 A",

}

TY - JOUR

T1 - Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma

AU - Fernandez-Pol, J. Albert

AU - Fletcher, James

AU - Hamilton, Paul D.

AU - Klos, Dennis J.

PY - 1997

Y1 - 1997

N2 - Background. We have previously shown that human metallopanstimulin (MPS-1) is a 9.4-kDa multifunctional ribosomal S27/nuclear 'zinc finger' protein which is expressed in a wide variety of actively proliferating cells and tumor tissues. Furthermore, we have shown that detection of MPS-N immunoreactive material in sera corresponding to the NH2 terminus of MPS-1 provides a method for determining the presence of certain types of abnormal proliferative conditions and/or active oncogenic processes in patients. In this study, we investigated MPS-N and MPS-N-like antigens present in the blood of patients with prostatic carcinoma (PC) and their relationship to the clinical status of patients with PC. Methods. The presence of MPS-N immunoreactive material was determined using a sensitive and specific radioimmunoassay (RIA) which has been developed to measure circulating levels of MPS-N antigen(s). In addition, MPS-N levels were compared to the primary bio-marker used in PC patient management, Prostatic Specific Antigen (PSA). Results. MPS-N concentations were determined in the blood of 107 males having no evidence of PC, and in 126 patients diagnosed with PC. In patients not having PC the MPS-N levels were lower than 10 ng/mL. In untreated patients having PC stages T1/T2, the MPS-N level range was 10-30 ng/mL; in stages T3/T4 the MPS-N level range was 30-50 ng/mL; and in stage Mlb (distant metastasis to the bones) the MPS-N levels were extremely high (> 50 ng/mL). In Mlb patients that did not respond to therapy the MPS-N levels remained very high (> 50 ng/mL). In Mlb patients that went into remission after treatment, the MPS-N levels were dramatically reduced. In addition, a comparison of the test properties of MPS-N and PSA for prostate cancer were evaluated in a total of 231 patients. In both the low and high value range, both MPS-N and PSA appear to be equally effective in modifying the probability of the target condition-prostatic cancer. Conclusions: These findings show that (1) in untreated PC patients, the increase in serum MPS-N correlated with the stage of the disease; (2) MPS-N tumor marker predicted the degree of aggressiveness of tumor growth and response to therapy. In summary despite the uncertainties of the relative contributions of the molecules being measured in cancer patients (authentic MPS-1, and MPS-N-like protein sequences), the MPS-N test is a pragmatic test that correlates well with active prostatic malignancy.

AB - Background. We have previously shown that human metallopanstimulin (MPS-1) is a 9.4-kDa multifunctional ribosomal S27/nuclear 'zinc finger' protein which is expressed in a wide variety of actively proliferating cells and tumor tissues. Furthermore, we have shown that detection of MPS-N immunoreactive material in sera corresponding to the NH2 terminus of MPS-1 provides a method for determining the presence of certain types of abnormal proliferative conditions and/or active oncogenic processes in patients. In this study, we investigated MPS-N and MPS-N-like antigens present in the blood of patients with prostatic carcinoma (PC) and their relationship to the clinical status of patients with PC. Methods. The presence of MPS-N immunoreactive material was determined using a sensitive and specific radioimmunoassay (RIA) which has been developed to measure circulating levels of MPS-N antigen(s). In addition, MPS-N levels were compared to the primary bio-marker used in PC patient management, Prostatic Specific Antigen (PSA). Results. MPS-N concentations were determined in the blood of 107 males having no evidence of PC, and in 126 patients diagnosed with PC. In patients not having PC the MPS-N levels were lower than 10 ng/mL. In untreated patients having PC stages T1/T2, the MPS-N level range was 10-30 ng/mL; in stages T3/T4 the MPS-N level range was 30-50 ng/mL; and in stage Mlb (distant metastasis to the bones) the MPS-N levels were extremely high (> 50 ng/mL). In Mlb patients that did not respond to therapy the MPS-N levels remained very high (> 50 ng/mL). In Mlb patients that went into remission after treatment, the MPS-N levels were dramatically reduced. In addition, a comparison of the test properties of MPS-N and PSA for prostate cancer were evaluated in a total of 231 patients. In both the low and high value range, both MPS-N and PSA appear to be equally effective in modifying the probability of the target condition-prostatic cancer. Conclusions: These findings show that (1) in untreated PC patients, the increase in serum MPS-N correlated with the stage of the disease; (2) MPS-N tumor marker predicted the degree of aggressiveness of tumor growth and response to therapy. In summary despite the uncertainties of the relative contributions of the molecules being measured in cancer patients (authentic MPS-1, and MPS-N-like protein sequences), the MPS-N test is a pragmatic test that correlates well with active prostatic malignancy.

KW - Metallopanstimulin

KW - Prostate cancer

KW - Ribosomal S27 protein

KW - Tumor markers

KW - Zing finger proteins

UR - http://www.scopus.com/inward/record.url?scp=0030909288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030909288&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 1519

EP - 1530

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 A

ER -